AIM： To study the relationship between anti-β2- glycoprotein Ⅰ （aβ2GPⅠ） antibodies and platelet activation state in patients with ulcerative colitis （UC） and its significance. METHODS： Peripheral blood sampl...AIM： To study the relationship between anti-β2- glycoprotein Ⅰ （aβ2GPⅠ） antibodies and platelet activation state in patients with ulcerative colitis （UC） and its significance. METHODS： Peripheral blood samples were collected from 56 UC patients （34 males and 22 females, aged 43.5 years, range 21-66 years）, including 36 at active stage and 20 at remission stage, and 25 sex-and age-matched controls. The level of aβ2GP Ⅰ was measured by ELISA. The platelet activation markers, platelet activation complex- Ⅰ （PAC- Ⅰ ） and P-selectin （CD62P） were detected by flow cytometry. RESULTS： The A value for IgG aβ2GP Ⅰ in the active UC group was 0.61 ± 0.13, significantly higher than that in the remittent UC and control groups （0.50 ± 0.13 and 0.22 ± 0.14, P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. The A value for IgM aβ2GP Ⅰ in the active and remittent UC groups was 0.43 ± 0.13 and 0.38 ± 0.12, significantly higher than that in the control group （0.20 ± 0.12, P 〈 0.01）. However, there was no significant difference between the two groups （P 〉 0.05）. The PAC- Ⅰ positive rate for the active and remittent UC groups was 30.6% ± 7.6% and 19.6% ± 7.8% respectively, significantly higher than that for the control group （6.3% ± 1.7%,P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. The CD62P positive rate for the active and remittent UC groups was 45.0% ± 8.8% and 31.9% ± 7.8% respectively, significantly higher than that for the control group （9.2% ± 2.7%, P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. In the active UC group, the more severe the state of illness was, the higher the A value for IgG aβ2GP Ⅰ was, and the positive rate for PAC-Ⅰ and CD62P was positively correlated with the state of illness （Faβ2GP Ⅰ = 3.679, P 〈 0.05; FPAC-Ⅰ （%） = 5.346, P 〈 0.01; and FCD62P （%） = 5. 418, P 〈 0.01）. Meanwhile, in the same state of illness, the A value for IgG aβ2GP Ⅰ was positively correlated to the positive rates for PAC-Ⅰ and CD62P. CONCLUSION： aβ2GP Ⅰ level, platelet activation state and their relationship of them are closely correlated with the pathogenesis and development of UC.展开更多
目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院...目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院的体检健康者51例作为对照组。依据梗死病灶范围将脑梗死患者分为大梗死组(梗死病灶>50 cm 2),中梗死组(梗死病灶在10~50 cm 2),小梗死组(梗死病灶<10 cm 2)。依据颈动脉彩超结果将脑梗死患者分为斑块期组、增厚期组、管壁正常组。采用酶联免疫吸附试验检测血清ZO-1、aβ2-GP1水平,并比较各组ZO-1、aβ2-GP1水平变化;采用Spearman相关分析脑梗死患者血清ZO-1、aβ2-GP1水平与梗死病灶范围及颈动脉粥样硬化程度的相关性。结果研究组血清ZO-1水平低于对照组,血清aβ2-GP1水平高于对照组(P<0.05)。在103例脑梗死患者中,大梗死组有32例,中梗死组有34例,小梗死组有37例,其中小梗死组ZO-1水平高于中梗死组和大梗死组,aβ2-GP1水平低于中梗死组和大梗死组(P<0.05);中梗死组ZO-1水平高于大梗死组,aβ2-GP1水平低于大梗死组(P<0.05)。在103例脑梗死患者中,斑块期组有29例,增厚期组有38例,管壁正常组有36例,其中斑块期组血清ZO-1水平低于增厚期组和管壁正常组,aβ2-GP1水平高于增厚期组和管壁正常组(P<0.05);增厚期组血清ZO-1水平低于管壁正常组,aβ2-GP1水平高于管壁正常组(P<0.05)。Spearman相关分析发现,脑梗死患者血清ZO-1水平与颈动脉粥样硬化程度和梗死病灶范围呈负相关(P<0.05),aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围呈正相关(P<0.05)。结论脑梗死患者血清ZO-1和aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围有着明显的相关性,在脑梗死患者的病情诊断、治疗和预后中具有潜在价值。展开更多
基金The National Natural Science Foundation of China, No. 30572106
文摘AIM： To study the relationship between anti-β2- glycoprotein Ⅰ （aβ2GPⅠ） antibodies and platelet activation state in patients with ulcerative colitis （UC） and its significance. METHODS： Peripheral blood samples were collected from 56 UC patients （34 males and 22 females, aged 43.5 years, range 21-66 years）, including 36 at active stage and 20 at remission stage, and 25 sex-and age-matched controls. The level of aβ2GP Ⅰ was measured by ELISA. The platelet activation markers, platelet activation complex- Ⅰ （PAC- Ⅰ ） and P-selectin （CD62P） were detected by flow cytometry. RESULTS： The A value for IgG aβ2GP Ⅰ in the active UC group was 0.61 ± 0.13, significantly higher than that in the remittent UC and control groups （0.50 ± 0.13 and 0.22 ± 0.14, P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. The A value for IgM aβ2GP Ⅰ in the active and remittent UC groups was 0.43 ± 0.13 and 0.38 ± 0.12, significantly higher than that in the control group （0.20 ± 0.12, P 〈 0.01）. However, there was no significant difference between the two groups （P 〉 0.05）. The PAC- Ⅰ positive rate for the active and remittent UC groups was 30.6% ± 7.6% and 19.6% ± 7.8% respectively, significantly higher than that for the control group （6.3% ± 1.7%,P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. The CD62P positive rate for the active and remittent UC groups was 45.0% ± 8.8% and 31.9% ± 7.8% respectively, significantly higher than that for the control group （9.2% ± 2.7%, P 〈 0.01）. There was a significant difference between the two groups （P 〈 0.01）. In the active UC group, the more severe the state of illness was, the higher the A value for IgG aβ2GP Ⅰ was, and the positive rate for PAC-Ⅰ and CD62P was positively correlated with the state of illness （Faβ2GP Ⅰ = 3.679, P 〈 0.05; FPAC-Ⅰ （%） = 5.346, P 〈 0.01; and FCD62P （%） = 5. 418, P 〈 0.01）. Meanwhile, in the same state of illness, the A value for IgG aβ2GP Ⅰ was positively correlated to the positive rates for PAC-Ⅰ and CD62P. CONCLUSION： aβ2GP Ⅰ level, platelet activation state and their relationship of them are closely correlated with the pathogenesis and development of UC.
文摘目的分析tau蛋白、胶质纤维状酸性蛋白(glial fibrillary acidic protein,GFAP)以及抗β2糖蛋白1抗体(anti-β2 glycoprotein 1 antibody,aβ2-GP1)水平与高血压脑出血(hypertensive intracerebral hemorrhage,HICH)患者预后的相关性。方法将70例HICH患者纳入研究组,另将同时期进行健康体检的70例人员纳入对照组。比较两组tau蛋白、GFAP以及aβ2-GP1水平。比较不同预后HICH患者tau蛋白、GFAP、aβ2-GP1水平和美国国立卫生院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分;并分析HICH患者相关指标与NIHSS评分的相关性。使用受试者工作特征(receiver operation characteristic,ROC)曲线分析相关指标预测HICH患者不良预后的临床价值。结果与对照组比较,观察组tau蛋白、GFAP以及aβ2-GP1水平均较高(P<0.05)。预后不良的HICH患者tau蛋白、GFAP、aβ2-GP1水平和NIHSS评分均较高(P<0.05);相关指标与NIHSS评分均呈正相关(均P<0.05)。相关指标预测HICH患者预后不良的最佳临界值:tau蛋白≥258.15ng/L、GFAP≥16.15ng/L、aβ2-GP1≥18.35 RU/mL,此时ROC曲线下面积(area under the curve,AUC)为0.908(95%CI:0.828~0.988,P<0.05)、0.871(95%CI:0.781~0.961,P<0.05)、0.839(95%CI:0.728~0.949,P<0.05),敏感度为77.27%、77.27%、72.73%,特异度为97.92%、85.42%、89.58%。结论HICH患者tau蛋白、GFAP以及aβ2-GP1水平较高,神经损伤较重、预后不良的HICH患者相关指标更高,监测HICH患者tau蛋白、GFAP以及aβ2-GP1水平可用于不良预后的评估。
文摘目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院的体检健康者51例作为对照组。依据梗死病灶范围将脑梗死患者分为大梗死组(梗死病灶>50 cm 2),中梗死组(梗死病灶在10~50 cm 2),小梗死组(梗死病灶<10 cm 2)。依据颈动脉彩超结果将脑梗死患者分为斑块期组、增厚期组、管壁正常组。采用酶联免疫吸附试验检测血清ZO-1、aβ2-GP1水平,并比较各组ZO-1、aβ2-GP1水平变化;采用Spearman相关分析脑梗死患者血清ZO-1、aβ2-GP1水平与梗死病灶范围及颈动脉粥样硬化程度的相关性。结果研究组血清ZO-1水平低于对照组,血清aβ2-GP1水平高于对照组(P<0.05)。在103例脑梗死患者中,大梗死组有32例,中梗死组有34例,小梗死组有37例,其中小梗死组ZO-1水平高于中梗死组和大梗死组,aβ2-GP1水平低于中梗死组和大梗死组(P<0.05);中梗死组ZO-1水平高于大梗死组,aβ2-GP1水平低于大梗死组(P<0.05)。在103例脑梗死患者中,斑块期组有29例,增厚期组有38例,管壁正常组有36例,其中斑块期组血清ZO-1水平低于增厚期组和管壁正常组,aβ2-GP1水平高于增厚期组和管壁正常组(P<0.05);增厚期组血清ZO-1水平低于管壁正常组,aβ2-GP1水平高于管壁正常组(P<0.05)。Spearman相关分析发现,脑梗死患者血清ZO-1水平与颈动脉粥样硬化程度和梗死病灶范围呈负相关(P<0.05),aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围呈正相关(P<0.05)。结论脑梗死患者血清ZO-1和aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围有着明显的相关性,在脑梗死患者的病情诊断、治疗和预后中具有潜在价值。
